Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

NCT00567554 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2600

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: epirubicin - cyclophosphamide / docetaxel
DRUG: epirubicin - cyclophosphamide / docetaxel + bevacizumab
DRUG: paclitaxel
DRUG: paclitaxel + everolimus (RAD001)
DRUG: epirubicin - cyclophosphamide / docetaxel + trastuzumab
DRUG: epirubicin - cyclophosphamide / docetaxel + lapatinib

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]